News & Updates

Data from the phase IV DUET* study presented at AAN 2025 reinforce the potential of low-sodium oxybate (LXB) for the treatment of narcolepsy or idiopathic hypersomnia (IH).

Combination treatment with esketamine plus either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is beneficial in treatment-resistant depression (TRD), with notable variations in outcomes depending on the choice of antidepressant class, as shown in a large retrospective study.